PLASMA-HORMONE LEVELS IN WOMEN RECEIVING NEW ORAL-CONTRACEPTIVES CONTAINING ETHINYL ESTRADIOL PLUS LEVONORGESTREL OR DESOGESTREL
PLASMA-HORMONE LEVELS IN WOMEN RECEIVING NEW ORAL-CONTRACEPTIVES CONTAINING ETHINYL ESTRADIOL PLUS LEVONORGESTREL OR DESOGESTREL
复制标题
DOI:
10.1016/0010-7824(83)90023-9
复制
发表时间:
1983-01-01
期刊:
影响因子:
2.9
通讯作者:
FRANCHIMONT, P
中科院分区:
文献类型:
--
作者:
GASPARD, UJ;ROMUS, MA;FRANCHIMONT, P
The changes in plasma hormone levels were evaluated in matched healthy female volunteers investigated before and after 6 mo. use of 3 new oral contraceptives (OC): Trigynon (n = 13), a triphasic OC containing low doses of ethynylestradiol (EE) + levonorgestrel (LNg); Marvelon (n = 14), a monophasic OC containing low doses of EE + desogestrel (DOG, a new progestogen derived from LNg); and Ovidol (n = 10), a sequential OC containing higher doses (50 .mu.g) of EE + DOG. Serum levels of FSH, LH [luteinizing hormone], estradiol and progesterone were decreased in all cases to levels incompatible with ovulation. Prolactin concentrations were unchanged. Sex hormone binding globulin (SHBG) and transcortin (CBG) levels were significantly increased by all 3 OC (Ovidol > Marvelon > Trigynon); free testosterone levels decreased significantly while free cortisol concentrations remained unchanged. All 3 OC are effective ovulation inhibitors, Ovidol and Marvelon have greater estrogenic effects than Trigynon, LNg is more effective than DOG in reducing the EE-induced increase in SHBG levels, and free testosterone levels are equally well suppressed by all 3 OC.